GFH375

GFH375 is a small-molecule drug developed by Genfleet Therapeutics (Shanghai). Its target is KRAS (the sponsor names KRAS G12D). The sponsor states: GFH375 is an oral, highly selective, non-covalent small-molecule inhibitor targeting the KRAS G12D mutation, blocking KRAS-driven signalling and cancer cell growth. ClinicalTrials.gov describes the intervention as: The experimental group receives GFH375 monotherapy, QD, orally. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07262567 (Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer) and NCT07668752 (A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation), in pancreatic ductal adenocarcinoma and non-small-cell lung cancer. The largest, NCT06500676, plans to enrol 407 participants with primary completion expected 2028-07-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.